Peroxisome Proliferator-Activated Receptor α Attenuates Hypertensive Vascular Remodeling by Protecting Vascular Smooth Muscle Cells from Angiotensin II-Induced ROS Production
Open Access
- 30 November 2022
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 11 (12) , 2378
Abstract
Vascular remodeling is the fundamental basis for hypertensive disease, in which vascular smooth muscle cell (VSMC) dysfunction plays an essential role. Previous studies suggest that the activation of peroxisome proliferator-activated receptor α (PPARα) by fibrate drugs has cardiovascular benefits independent of the lipid-lowering effects. However, the underlying mechanism remains incompletely understood. This study explored the role of PPARα in angiotensin II (Ang II)-induced vascular remodeling and hypertension using VSMC-specific Ppara-deficient mice. The PPARα expression was markedly downregulated in the VSMCs upon Ang II treatment. A PPARα deficiency in the VSMC significantly aggravated the Ang II-induced hypertension and vascular stiffness, with little influence on the cardiac function. The morphological analyses demonstrated that VSMC-specific Ppara-deficient mice exhibited an aggravated vascular remodeling and oxidative stress. In vitro, a PPARα deficiency dramatically increased the production of mitochondrial reactive oxidative species (ROS) in Ang II-treated primary VSMCs. Finally, the PPARα activation by Wy14643 improved the Ang II-induced ROS production and vascular remodeling in a VSMC PPARα-dependent manner. Taken together, these data suggest that PPARα plays a critical protective role in Ang II-induced hypertension via attenuating ROS production in VSMCs, thus providing a potential therapeutic target for hypertensive diseases.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFA0805100, 82070474, 91739120, CIT&TCD20190332, KZ202010025032)
- National Natural Science Foundation of China (2021YFA0805100, 82070474, 91739120, CIT&TCD20190332, KZ202010025032)
- National Natural Science Foundation of China (2021YFA0805100, 82070474, 91739120, CIT&TCD20190332, KZ202010025032)
- Support Project of High-level Teachers in Beijing Municipal Universities in the Period of the 13th Five-year Plan (2021YFA0805100, 82070474, 91739120, CIT&TCD20190332, KZ202010025032)
- The Key Science and Technology Project of Beijing Municipal Institutions (2021YFA0805100, 82070474, 91739120, CIT&TCD20190332, KZ202010025032)
This publication has 46 references indexed in Scilit:
- Prostacyclin and PPARα Agonists Control Vascular Smooth Muscle Cell Apoptosis and Phenotypic Switch through Distinct 14-3-3 IsoformsPLOS ONE, 2013
- Peroxisome Proliferator–Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Oxidative Stress and Vascular Damage in Hypertension: Role of Angiotensin IIInternational Journal of Hypertension, 2011
- Hypertension Prevalence, Awareness, Treatment, and Control in MozambiqueHypertension, 2009
- The PPARα/p16 INK4a Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle–Dependent Telomerase ActivationCirculation Research, 2008
- Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertensionKidney International, 2008
- Nongenomic Actions of Aldosterone on the Renal TubuleHypertension, 2007
- Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α ActivatorsHypertension, 2005
- Vascular Hypertrophy in Angiotensin II–Induced Hypertension Is Mediated by Vascular Smooth Muscle Cell–Derived H 2 O 2Hypertension, 2005
- PPARα Activator Effects on Ang II–Induced Vascular Oxidative Stress and InflammationHypertension, 2002